财务表现 - Accuray Q2财报显示每股亏损10美分，较去年同期的每股亏损2美分扩大，也超过了Zacks Consensus Estimate的每股亏损7美分[3] - 第二季度财报显示Accuray的营收为1.072亿美元，同比下降6.6%，但略高于Zacks Consensus Estimate[4] - 净营收为1.06亿美元，同比下降8%[6] 营收构成 - 产品营收下降，服务营收有所增长，整体营收增长受到产品营收下降的影响[5] - Accuray的营收主要来自产品和服务两个方面[7] - 产品营收从去年同期的5150万美元下降了18.5%，主要是由于年度出货量减少[8] - 服务营收从去年同期的5570万美元增长了8.2%，主要受合同收入增加和安装、培训及备件销售量增加的推动[9] 费用和利润 - 毛利润下降16.4%至3590万美元，毛利率下降396个基点至33.5%[10] - 销售和市场费用下降16.4%至1140万美元，研发费用同比增长4.4%至1530万美元，总部和行政费用同比增长9.9%至1320万美元[11] - 第二季度运营亏损为390万美元，而去年同期运营利润为270万美元[12] 财务展望 - Accuray预计第三季度营收在1.12亿至1.18亿美元之间，全年营收预计在4.6亿至4.7亿美元之间，同比增长3-5%[16][17] - 分析师在过去两个月内没有发布任何盈利预期修订，共识预期由于这些变化而下调了100%[18]

Company to Take Part in Fireside Chat Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST MADISON, Wis., Feb. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference taking place March 12-13, 2024. The management team is scheduled to participate in a fireside chat on Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST. A live webcast of the fireside chat can be accessed on the Accuray website at in ...

While most financial advisors will probably steer you away from under $5 stocks, they have their benefits. Just like in football – the American kind – you can’t just run up the gut. Well, technically, you can. That’s where the phrase three yards and a cloud of dust basically originated. If you hold onto the ball and keep marching down the field, you eat up the clock and deny opportunities to your opposition. However, the problem with this rather unimaginative strategy is that stuff happens. And that stuff – ...

公司前景展望 - Accuray Incorporated (ARAY)在未来几个季度有望实现增长，主要得益于其产品持续稳定的需求[1] - 公司在2024财年第二季度的表现和Precision Treatment Planning System (TPS)的潜力将进一步推动乐观情绪[1] - 然而，公司存在对技术的过度依赖和激烈的竞争[1]

Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is a center of excellence and recognized leader in the treatment of cancer in the province of Quebec The Radixact System is equipped with ClearRT™ and Synchrony®, advanced technologies designed to improve treatment outcomes for more patients each day MADISON, Wis., Feb. 13, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the team at Quebec's Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33301 ACCURAY INCORPORATED (Exact name of registrant as specified in its charter) Delaware 20-8370041 (State or other jurisdiction of ( ...

公司概况 - Accuray Incorporated宣布将参加BTIG MedTech、数字健康、生命科学和诊断工具会议[1] - Accuray致力于扩大放射治疗的潜力，为尽可能多的人提供改善生活的机会[3] - Accuray总部位于威斯康星州麦迪逊，拥有全球设施[3] 联系信息 - 投资者联系人为Aman Patel，媒体联系人为Beth Kaplan[4]

Accuray Incorporated (ARAY) reported loss per share of 10 cents for the second quarter of fiscal 2024, wider than the year-ago period’s loss of 2 cents per share. The metric was also wider than the Zacks Consensus Estimate of a loss of 7 cents per share. Revenues in Detail Accuray registered revenues of $107.2 million in the second quarter of fiscal 2024, down 6.6% year over year. The figure, however, topped the Zacks Consensus Estimate by 0.1%. The overall top-line growth was dampened by lower Products rev ...

业绩总结 - Accuray在2024财年第二季度取得了强劲的订单增长，订单金额达到9400万美元，同比增长19%[14] - 第二季度净收入为1.07亿美元，环比增长3%，同比下降7%[36] - 服务收入为季度5600万美元，同比增长8%[37] - 产品收入为季度5200万美元，同比下降19%[38] - 第二季度总毛利率为33.5%，较去年同期的37.4%下降[40] - 第二季度调整后的EBITDA为200万美元，较去年同期的850万美元下降[43] - 总现金、现金等价物和短期限制性现金为7300万美元[44] - 全年FY24指导预期为4.6亿至4.7亿美元的收入和2700万至3000万美元的调整后的EBITDA[45] - 预计第三季度收入表现在1.12亿至1.18亿美元的范围内，预期调整后的EBITDA范围为600万至900万美元[48] 用户数据 - 全球安装需求强劲，全球系统安装基数同比增长6%，APAC地区安装基数同比增长13%[21] - EIMEA地区订单和收入同比增长30%和11%，APAC地区订单同比增长42%，中国订单同比增长44%[23] - 日本地区订单同比增长8%，服务收入同比增长10%，但总收入因产品出货量较低而同比下降29%[26] - 美洲地区订单同比增长72%，主要得益于专注于为客户提供增值解决方案以保留和增长安装基数的商业策略[27] 未来展望 - 新产品推出如VitalHold、Tomo C和Helix等将成为未来收入和利润增长的增长点，预计将在2024财年第四季度和2025财年加速收入和利润增长[13] - 预计在Q4将看到Tomo C交付后的中国利润延迟[57] - 公司期待在印度市场获得正面的反应，尽管目前还为时过早[73] 新产品和新技术研发 - 新产品推出如VitalHold、Tomo C和Helix等将成为未来收入和利润增长的增长点，预计将在2024财年第四季度和2025财年加速收入和利润增长[13] - 中国市场Tomo C订单季度增长[55] - VitalHold在日本市场表现强劲，预计将在Q4有相关订单发货[56] - Tomo C在中国市场的反应非常强烈，公司对市场反应感到非常满意[70] 市场扩张和并购 - 公司将于今年春季再次举行财报电话会议，届时期待与大家再次交流[79]

Accuray (ARAY) reported $107.24 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 6.6%. EPS of -$0.10 for the same period compares to -$0.02 a year ago. The reported revenue represents a surprise of +0.12% over the Zacks Consensus Estimate of $107.11 million. With the consensus EPS estimate being -$0.07, the EPS surprise was -42.86%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall ...